Calming Alternatives Learned During MRI-Guided Breast Biopsy (CALM)

September 23, 2020 updated by: Duke University

Calming Alternatives Learned During MRI-Guided Breast Biopsy (CALM)

The proposed randomized study evaluates whether a controlled breathing intervention could be efficacious for reducing pain in the MRI-guided breast biopsy setting. Support for this intervention stems from experimental and clinical studies on the effects of controlled breathing on pain. Implementing a controlled breathing intervention during MRI-guided breast biopsy has the potential to provide effective pain management in this outpatient setting. The primary study objectives are to assess the feasibility, acceptability, and efficacy of a novel audio-recorded controlled breathing intervention for reducing breast and body pain in women undergoing MRI-guided breast biopsy. The secondary study objectives are to evaluate the effects of controlled breathing on measures of physiological reactivity (i.e., blood pressure and heart rate), pain catastrophizing, and self-efficacy for pain and anxiety.

Study Overview

Study Type

Interventional

Enrollment (Actual)

58

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • North Carolina
      • Durham, North Carolina, United States, 27710
        • Duke Cancer Institute

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

No

Genders Eligible for Study

Female

Description

Inclusion Criteria:

  • Women undergoing MRI-guided core needle breast biopsy at the Duke Cancer Institute
  • Ability to speak and read in English
  • Age ≥ 18 years
  • Ability to provide meaningful consent

Exclusion Criteria:

  • Hearing impairment that is documented in the medical record that would limit the use of the guided intervention or music
  • Cognitive impairment that is documented in the medical record or results in being unable to provide meaningful consent
  • Undergoing IV-administered sedation

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: TREATMENT
  • Allocation: RANDOMIZED
  • Interventional Model: PARALLEL
  • Masking: SINGLE

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
NO_INTERVENTION: Usual Care Control Condition
As part of usual care, participants will be provided with headphones to listen to music during the biopsy procedure. Music options will include instrumental jazz, classical piano, harp and flute, and world music.
EXPERIMENTAL: Controlled Breathing Intervention
Participants in the controlled breathing intervention will be provided with headphones to listen to the guided intervention audio file. Over the course of the 25-60-minute procedure, approximately 50% of the intervention will be spent completing controlled breathing. The other 50% of the intervention will be spent listening to music, which is part of usual care. Music options will include instrumental jazz, classical piano, harp and flute, nature sounds, and world music.
Participants in the controlled breathing intervention will be provided with headphones to listen to the guided intervention audio file. The intervention will guide participants to breathe at a rate of six breaths per minute (approximately 50% of their normal breathing rate).

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Body pain pre-biopsy: Brief Pain Inventory (BPI) Pain Severity Scale
Time Frame: Baseline
Body pain pre-biopsy will be will be assessed using four questions from the Brief Pain Inventory (BPI) Pain Severity Scale. Women will be asked to rate 1) worst, 2) least, and 3) average body pain during the past week, as well as 4) current body pain on a scale from 0 (no pain) to 10 (pain as bad as it could be). Consistent with BPI scoring, items will be averaged to create a composite score that had a possible range of 0 to 10 with higher scores indicating greater pain.
Baseline
Breast pain pre-biopsy: Brief Pain Inventory (BPI) Pain Severity Scale
Time Frame: Baseline
Breast pain pre-biopsy will be will be assessed using four questions from the Brief Pain Inventory (BPI) Pain Severity Scale. Women will be asked to rate 1) worst, 2) least, and 3) average breast pain during the past week, as well as 4) current breast pain on a scale from 0 (no pain) to 10 (pain as bad as it could be). Consistent with BPI scoring, items will be averaged to create a composite score that had a possible range of 0 to 10 with higher scores indicating greater pain.
Baseline
Body pain after positioning on the MRI table: Numerical rating scale (NRS)
Time Frame: After positioning on the MRI table, within 1 minute
Body pain after positioning on the MRI table for the biopsy procedure will be will be assessed using a verbally-administered numerical rating scale (NRS) that ranges from 0 (no pain) to 10 (pain as bad as it could be) with higher scores indicating greater pain.
After positioning on the MRI table, within 1 minute
Breast pain after local anesthetic injection: Numerical rating scale (NRS)
Time Frame: After each superficial local anesthetic injection, within 1 minute
Breast pain after each superficial local anesthetic injection during the biopsy procedure will be will be assessed using a verbally-administered numerical rating scale (NRS) that ranges from 0 (no pain) to 10 (pain as bad as it could be) with higher scores indicating greater pain.
After each superficial local anesthetic injection, within 1 minute
Breast pain after deeper local anesthetic injection: Numerical rating scale (NRS)
Time Frame: After each deeper local anesthetic injection, within 1 minute
Breast pain after each deeper local anesthetic injection during the biopsy procedure will be will be assessed using a verbally-administered numerical rating scale (NRS) that ranges from 0 (no pain) to 10 (pain as bad as it could be) with higher scores indicating greater pain.
After each deeper local anesthetic injection, within 1 minute
Body pain after introducer insertion: Numerical rating scale (NRS)
Time Frame: After last introducer insertion, within 1 minute
Body pain after the last introducer is inserted will be will be assessed using a verbally-administered numerical rating scale (NRS) that ranges from 0 (no pain) to 10 (pain as bad as it could be) with higher scores indicating greater pain.
After last introducer insertion, within 1 minute
Breast pain after tissue sampling: Numerical rating scale (NRS)
Time Frame: After last tissue sampling at each biopsy site, within 1 minute
Breast pain after the last tissue sampling at each biopsy site will be will be assessed using a verbally-administered numerical rating scale (NRS) that ranges from 0 (no pain) to 10 (pain as bad as it could be) with higher scores indicating greater pain.
After last tissue sampling at each biopsy site, within 1 minute
Body pain after introducer sheath removal: Numerical rating scale (NRS)
Time Frame: After last introducer sheath removal, within 1 minute
Body pain after the last introducer sheath is removed will be will be assessed using a verbally-administered numerical rating scale (NRS) that ranges from 0 (no pain) to 10 (pain as bad as it could be) with higher scores indicating greater pain.
After last introducer sheath removal, within 1 minute
Body pain post-biopsy: Brief Pain Inventory (BPI) Pain Severity Scale
Time Frame: Post-biopsy, within 1 minute
Body pain post-biopsy will be will be assessed using four questions from the Brief Pain Inventory (BPI) Pain Severity Scale. Women will be asked to rate 1) worst, 2) least, and 3) average body pain during the biopsy procedure, as well as 4) current body pain on a scale from 0 (no pain) to 10 (pain as bad as it could be). Consistent with BPI scoring, items will be averaged to create a composite score that had a possible range of 0 to 10 with higher scores indicating greater pain.
Post-biopsy, within 1 minute
Breast pain post-biopsy: Brief Pain Inventory (BPI) Pain Severity Scale
Time Frame: Post-biopsy, within 1 minute
Breast pain post-biopsy will be will be assessed using four questions from the Brief Pain Inventory (BPI) Pain Severity Scale. Women will be asked to rate 1) worst, 2) least, and 3) average breast pain during the biopsy procedure, as well as 4) current breast pain on a scale from 0 (no pain) to 10 (pain as bad as it could be). Consistent with BPI scoring, items will be averaged to create a composite score that had a possible range of 0 to 10 with higher scores indicating greater pain.
Post-biopsy, within 1 minute
Body pain 24 hours post-biopsy: Brief Pain Inventory (BPI) Pain Severity Scale
Time Frame: 24 hours post-biopsy
Body pain 24 hours post-biopsy will be will be assessed using four questions from the Brief Pain Inventory (BPI) Pain Severity Scale. Women will be asked to rate 1) worst, 2) least, and 3) average body pain in the 24 hours post-biopsy, as well as 4) current body pain on a scale from 0 (no pain) to 10 (pain as bad as it could be). Consistent with BPI scoring, items will be averaged to create a composite score that had a possible range of 0 to 10 with higher scores indicating greater pain.
24 hours post-biopsy
Breast pain 24 hours post-biopsy: Brief Pain Inventory (BPI) Pain Severity Scale
Time Frame: 24 hours post-biopsy
Breast pain 24 hours post-biopsy will be will be assessed using four questions from the Brief Pain Inventory (BPI) Pain Severity Scale. Women will be asked to rate 1) worst, 2) least, and 3) average breast pain in the 24 hours post-biopsy, as well as 4) current breast pain on a scale from 0 (no pain) to 10 (pain as bad as it could be). Consistent with BPI scoring, items will be averaged to create a composite score that had a possible range of 0 to 10 with higher scores indicating greater pain.
24 hours post-biopsy

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Number of pre-biopsy body pain sites: Body map
Time Frame: Baseline
To indicate the number of pre-biopsy body pain sites, participants will complete a full body map, indicating the locations of body pain.
Baseline
Number of pre-biopsy breast pain sites: Breast map
Time Frame: Baseline
To indicate the number of pre-biopsy breast pain sites, participants will complete a breast map (showing the chest, shoulders, and upper arms), indicating the locations of breast pain.
Baseline
Anticipated body pain: Anticipatory body pain scale
Time Frame: Baseline
Prior to biopsy, one question will be asked to assess anticipated body pain (i.e., "How much body pain do you think you will experience during the biopsy today?") on a scale from 0 (no pain) to 10 (pain as bad as it could be) with higher scores indicating greater anticipated pain.
Baseline
Anticipated breast pain: Anticipatory breast pain scale
Time Frame: Baseline
Prior to biopsy, one question will be asked to assess anticipated breast pain (i.e., "How much breast pain do you think you will experience during the biopsy today?") on a scale from 0 (no pain) to 10 (pain as bad as it could be) with higher scores indicating greater anticipated pain.
Baseline
Anxiety pre-biopsy: State Anxiety Scale of the State-Trait Anxiety Inventory (STAI)
Time Frame: Baseline
The State Anxiety Scale of the State-Trait Anxiety Inventory (STAI) will assess the degree of anxiety pre-biopsy. Participants will rate each of the 20 items on a 5-point Likert scale, ranging from 1 (not at all) through 4 (very much). Items will be summed, creating a total score (possible range: 20-80).
Baseline
Likelihood of cancer pre-biopsy: Likelihood of cancer scale
Time Frame: Baseline
Likelihood of cancer will be assessed pre-biopsy using a 1 single-item scale. Participants will be asked to indicate what they were told regarding the likelihood of cancer from their recommending radiologist on a scale from 0 (not applicable - they did not discuss this with me) to 5 (high likelihood of cancer) with higher scores indicating a greater likelihood of cancer.
Baseline
Pain coping strategies pre-biopsy: Coping Strategies Questionnaire (CSQ)
Time Frame: Baseline
To assess the use of pain coping strategies pre-biopsy, participants will complete the 14-item Coping Strategies Questionnaire (CSQ). Participants will rate how frequently they use seven pain coping strategies (two items per scale) on a scale ranging from 0 (not at all) to 6 (a lot). Items will be averaged, giving a total score on each scale ranging from 0 to 6 with higher scores indicating greater use of pain coping strategies.
Baseline
Self-efficacy for pain and anxiety pre-biopsy: Self-efficacy for pain and anxiety scale
Time Frame: Baseline
To assess self-efficacy for managing pain and anxiety pre-biopsy, participants will complete a 4-item scale. Items will be rated on a 10-point scale from 1 (not certain) to 10 (very certain). Items will be averaged to create a composite score, ranging from 0 to 10 with higher scores indicating greater self-efficacy.
Baseline
Blood pressure pre-biopsy
Time Frame: Baseline
Blood pressure (systolic/diastolic) pre-biopsy will be measured using an MRI-compatible blood pressure cuff.
Baseline
Pulse pre-biopsy
Time Frame: Baseline
Heart rate pre-biopsy will be measured using an MRI-compatible pulse oximeter.
Baseline
Blood pressure after positioning on the MRI table
Time Frame: After positioning on the MRI table, within 1 minute
Blood pressure (systolic/diastolic) after positioning on the MRI table will be measured using an MRI-compatible blood pressure cuff.
After positioning on the MRI table, within 1 minute
Pulse after positioning on the MRI table
Time Frame: After positioning on the MRI table, within 1 minute
Heart rate after positioning on the MRI table will be measured using an MRI-compatible pulse oximeter.
After positioning on the MRI table, within 1 minute
Blood pressure after introducer insertion
Time Frame: After last introducer insertion, within 1 minute
Blood pressure (systolic/diastolic) after the last introducer is inserted will be measured using an MRI-compatible blood pressure cuff.
After last introducer insertion, within 1 minute
Pulse after after introducer insertion
Time Frame: After last introducer insertion, within 1 minute
Heart rate after the last introducer is inserted will be measured using an MRI-compatible pulse oximeter.
After last introducer insertion, within 1 minute
Blood pressure after introducer sheath removal
Time Frame: After last introducer sheath removal, within 1 minute
Blood pressure (systolic/diastolic) after the last introducer sheath is removed will be measured using an MRI-compatible blood pressure cuff.
After last introducer sheath removal, within 1 minute
Pulse after introducer sheath removal
Time Frame: After last introducer sheath removal, within 1 minute
Heart rate after the last introducer sheath is removed will be measured using an MRI-compatible pulse oximeter.
After last introducer sheath removal, within 1 minute
Anxiety post-biopsy: State Anxiety Scale of the State-Trait Anxiety Inventory (STAI)
Time Frame: Post-biopsy, within 1 hour
The State Anxiety Scale of the State-Trait Anxiety Inventory (STAI) will assess the degree of anxiety post-biopsy. Participants will rate each of the 20 items on a 5-point Likert scale, ranging from 1 (not at all) through 4 (very much). Items will be summed, creating a total score (possible range: 20-80).
Post-biopsy, within 1 hour
Likelihood of cancer post-biopsy: Likelihood of cancer scale
Time Frame: Post-biopsy, within 1 hour
Likelihood of cancer will be assessed post-biopsy using a single-item scale. Participants will be asked to indicate what they were told regarding the likelihood of cancer from the radiologist performing the biopsy on a scale from 0 (not applicable - they did not discuss this with me) to 5 (high likelihood of cancer).
Post-biopsy, within 1 hour
Distraction from pain during biopsy: Attention to pain scale
Time Frame: Post-biopsy, within 1 hour
Using a 2-item self-report measure, participants will rate 1) the amount of attention they paid to the pain during biopsy and 2) the extent to which they were able to distract themselves from the pain during biopsy on an 11-point scale, ranging from 0 (not at all) to 10 (very much). An ''attention to pain" score (range -10 to +10) will be calculated by subtracting the ability to distract from pain from the amount of attention to pain. The higher the score, the more attention paid to pain.
Post-biopsy, within 1 hour
Distraction from pain during biopsy: Time spent thinking about pain scale
Time Frame: Post-biopsy, within 1 hour
Participants will also be asked to rate how much time they spent thinking about pain during the biopsy procedure on an 11-point scale, ranging from 0 (none of the time) to 10 (all of the time).
Post-biopsy, within 1 hour
Relaxation during biopsy: Relaxation numerical rating scale (NRS)
Time Frame: Post-biopsy, within 1 hour
Participants will be asked to indicate how relaxed they were during the biopsy procedure on a scale, ranging from 0 (not relaxed) to 10 (extremely relaxed).
Post-biopsy, within 1 hour
Relaxation during biopsy: Tension Subscale of the Profile of Mood State Short-Form
Time Frame: Post-biopsy, within 1 hour
Participants will also be provided with a list of six adjectives (i.e., tense, on-edge, uneasy, restless, nervous, and anxious) from the Tension Subscale of the Profile of Mood State Short-Form and be asked to rate each of the adjectives on a 5-point Likert scale, ranging from 0 (not at all) to 4 (extremely).
Post-biopsy, within 1 hour
Pain coping strategies post-biopsy: Coping Strategies Questionnaire (CSQ)
Time Frame: Post-biopsy, within 1 hour
To assess the use of pain coping strategies during the biopsy procedure, participants will complete the 14-item Coping Strategies Questionnaire (CSQ). Participants will rate how frequently they used seven pain coping strategies (two items per scale) during the procedure on a scale ranging from 0 (not at all) to 6 (a lot). Items will be averaged, giving a total score on each scale ranging from 0 to 6 with higher scores indicating greater use of pain coping strategies.
Post-biopsy, within 1 hour
Self-efficacy for pain and anxiety during biopsy: Self-efficacy for pain and anxiety scale
Time Frame: Post-biopsy, within 1 hour
To assess self-efficacy for managing pain and anxiety during the biopsy procedure, participants will complete a 4-item scale. Items will be rated on a 10-point scale from 0 (not certain) to 10 (very certain). Items will be averaged to create a composite score, ranging from 0 to 10 with higher scores indicating greater self-efficacy.
Post-biopsy, within 1 hour
Anxiety 24 hours post-biopsy: State Anxiety Scale of the State-Trait Anxiety Inventory (STAI)
Time Frame: 24 hours post-biopsy
The State Anxiety Scale of the State-Trait Anxiety Inventory (STAI) will assess the degree of anxiety 24 hours post-biopsy. Participants will rate each of the 20 items on a 5-point Likert scale, ranging from 1 (not at all) through 4 (very much). Items will be summed, creating a total score (possible range: 20-80).
24 hours post-biopsy

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Investigators

  • Principal Investigator: Rebecca Shelby, Ph.D., Duke Psychiatry and Behavioral Sciences

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ACTUAL)

October 16, 2018

Primary Completion (ACTUAL)

June 20, 2019

Study Completion (ACTUAL)

June 20, 2019

Study Registration Dates

First Submitted

February 26, 2019

First Submitted That Met QC Criteria

March 14, 2019

First Posted (ACTUAL)

March 15, 2019

Study Record Updates

Last Update Posted (ACTUAL)

September 25, 2020

Last Update Submitted That Met QC Criteria

September 23, 2020

Last Verified

November 1, 2018

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Breast Cancer

Clinical Trials on Controlled Breathing Intervention

3
Subscribe